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Abstract 
Introduction: Intraventricular haemorrhage (IVH) is a subtype of intracerebral haemorrhage (ICH), with 50% 
mortality and serious disability for survivors. CLEAR III, a randomised, double-blinded, placebo-controlled trial 
of subjects with a routinely-placed extraventricular drain (EVD), tested whether attempting to remove IVH with 
alteplase vs. saline irrigation improved functional outcome.  
Methods: Patients in the intensive care unit with stable, non-traumatic ICH volume <30 mL, IVH obstructing 
the 3rd or 4th ventricles, and no underlying pathology were adaptively randomised (1:1) to receive up to 12 
doses, 8 hours apart of 1mg of alteplase or 0.9% saline via the EVD. CT scans were obtained every 24 hours 
throughout dosing. The primary efficacy outcome was good functional outcome, defined as a modified Rankin 
Scale score of ≤3 at 180 days (mRS) per central adjudication by blinded evaluators. 
Results: The trial completed with 180-day follow-up data available for analysis from 246/251 and 245/249 
subjects in the alteplase and placebo groups, respectively. The primary efficacy outcome was similar in each 
arm (good outcome in alteplase group 48% vs. saline 45%; RR (95% CI)=1.06 (0.88, 128) p=0.554). A 
difference of 3.5% (RR (95% CI)=1.08 (0.90, 1.29), p=0.420) was found after adjusting for IVH size and 
thalamic ICH. At 180 days, the treatment arm had lower case fatality (18% vs. saline 29%, HR (95% CI)=0.60 
(0.41, 0.86), p=0.006), but greater proportion with mRS 5 (17% vs. 9%; RR (95% CI)=1.99 (1.22, 3.26), p 
=0.005). Ventriculitis (7% alteplase vs. 12%; RR (95% CI)=0.55 (0.31, 0.97), p=0.048), and serious adverse 
events (49% alteplase vs. 63%; RR (95% CI)=0.77 (0.66, 0.91), p=0.002), were less frequent with alteplase 
treatment. Symptomatic bleeding (2%, both arms; RR (95% CI)=1.21 (0.37, 3.91), p=0.771) was similar.  
Conclusions:  In patients with IVH and a routine EVD, irrigation with alteplase did not substantially improve 
functional outcomes at the mRS 3 cutoff compared to irrigation with saline. Protocol-based use of alteplase 
with EVD appears safe. Future investigation is needed to determine if a greater frequency of complete IVH 
removal via alteplase produces gains in functional status.    
 
 
(Funded by the National Institute of Neurological Disorders and Stroke; ClinicalTrials.gov NCT00784134.) 
Word count with research in context is 4669 
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Introduction: In patients with spontaneous intracerebral haemorrhage (ICH), intraventricular haemorrhage 
(IVH) is associated with devastating consequences.1-4 Mortality is reported to be greater than 50%, with fewer 
than 20% of survivors having good functional outcomes. Mortality and function appear to be altered if 
thrombolytic is employed.5,6 Systematic review, Meta-analysis suggest removal of IVH improves survival and 
long-term functional outcome by relieving acute obstructive hydrocephalus and reducing neurotoxicity.5-9 We 
hypothesised that small ICH with large IVH describes a subgroup of ICH patients whose severe prognosis is 
reversible.1,6 Thus we organised the Phase III Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR III) 
trial.  
 
In EVD-treated IVH subjects, we tested the hypothesis that irrigating the ventricle with alteplase would be 
superior to normal saline (0.9%), measured by an improved modified Rankin Scale (mRS) score 0-3 (mRS ≤3, 
called “good outcome”), in which a score of 0 indicates no symptoms, a score of 5 indicates severe disability, 
and a score of 6 indicates death. This hypothesis was based on our preliminary data showing alteplase 
(Genentech, Inc., San Francisco, CA) can safely remove clot from the ventricle, if precautions are taken to 
avoid re-activating brain bleeding, in patients treated with an EVD.10-13 Although EVD placement is not 
standardised in practice for all cases of IVH, it is used to manage hydrocephalus and intracranial pressure 
(ICP). We included such patients in the CLEAR III study.  
 
Methods  
 
Trial Design and Participants: CLEAR III was a multicentre, randomised (1:1), prospective phase III trial11 
done at 73 sites in the US, Canada, Brazil, Israel, UK, Germany, Hungary, and Spain, following local and 
country ethics approval, testing a strategy of ventricular clearance with alteplase via EVDs placed for ICP 
control in subjects with a clinical diagnosis of obstructive hydrocephalus. Placement of an EVD pre-trial was a 
routine clinical care decision. Subjects were age 18-80 with known symptom onset within 24 hours of the initial 
computed tomography (CT) scan confirming IVH and 3rd or 4th ventricle obstruction. Eligibility criteria included 
supratentorial ICH volume ≤30 mL, measured by the ABC/2 method,12 and clot stability (no measured 
expansion >5 mL) on repeat CT scan at least 6 hours after EVD placement.13 Additional eligibility criteria 
5 
included an historical mRS ≤1, no limitations to care, and no ongoing coagulopathy, suspicion of aneurysm, 
arteriovenous malformation, or other vascular anomaly.13 (See supplemental appendix, section 2a. 
Methodological details of the treatment protocol: Inclusion and Exclusion criteria for additional details.) All data 
were captured electronically and pertinent source documentation uploaded by local site personnel using an 
internet-based electronic data capture (EDC) system (VISION, Prelude Dynamics, LLC, Austin, Tx). The EDC 
provided field-level and form-to-form range and value edit checks during data entry. Independent quality 
assurance monitors (Emissary International, LLC, Austin, Tx) utilized the uploaded source documentation to 
perform risk-based, remote monitoring of key data variables. Monitored data were then exported by the data 
management center where additional data edit checks were applied prior to form/subject finalization. Site 
personnel were notified of and responded to data discrepancies identified during these review processes using 
the EDC system query tool, with resulting data corrections captured by the electronic audit trail. 
 
Randomization and Blinding: All subjects and trial personnel except for the local and central pharmacists 
and the unblinded statistician were masked to treatment assignments. After the local PI determined eligibility 
and written, informed consent was obtained, site personnel randomised patients within 72 hours of ictus using 
a web-based enrollment system (VISION, Prelude Dynamics, LLC, Austin, Tx), which generated a treatment 
allocation and emailed the treatment assignment code directly to the local, trained pharmacist. All other site 
and coordinating center personnel remained blinded to allocation.  After 100 subjects were assigned by simple 
randomisation, a Pocock-Simon14,15.covariate adaptive algorithm was implemented to balance study arms by 
baseline IVH size (≤20 mL; 20-50 mL; and >50 mL, measured on the diagnostic CT), ICH location (thalamus or 
other, determined by centralised CT reading). Imbalances in these factors were determined at each enrollment, 
and patients were randomised with a weighted coin (80/20) favoring assignment to the treatment arm, which 
improved balance in ICH location and ICH size. 6,13,14 To ensure treatment balance at the site, patients were 
adaptively randomised only after a given site had recruited two saline and two alteplase patients. All 
participants remained masked during data collection and interim analyses. Masking was evaluated by 
the external monitor.  
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Treatment: Subjects received up to 12 doses, 8 hours apart, of 1 mg of alteplase or 0.9% saline via the EVD. 
CT scans were obtained every 24 hours throughout dosing. All subjects were managed using the American 
Heart Association recommendations for the treatment of spontaneous ICH as the basis for a standard 
approach to airway, ventilation, ICP monitoring, sedation and pharmacologic treatment of mass effect.16,17 
Investigators were asked to remove as much clot as possible, until a stopping point was obtained: 3rd and 4th 
ventricles open; IVH mass effect relieved; 80% of clot was removed; or 12 doses were given.   
 
Image analysis: To optimize accuracy and minimize investigator bias, clot volumes were analyzed by a core 
laboratory utilizing semi-automated segmentation and Hounsfield thresholds.18 This was performed using 
OsiriX software (v.4.1, Pixmeo; Geneva, Switzerland) on DICOM images of each subject’s stability and 
treatment scans. This approach has been validated for accuracy and inter-rater reliability.19 Core lab values 
were utilized in all analyses. Core lab defined location as either thalamus or other (lobar, putamen, caudate). 
 
Follow-up and Outcomes: Subjects were followed with an NIHSS assessment at Day 7, clinic visits on Days 
30, 180, and 365, and phone contacts at Days 90 and 270. A site-identified, certified examiner assessed the 
mRS, extended Glasgow Outcome Scale (eGOS; 8 level disability scale from 8-upper good recovery to 1-
death), Barthel Index (BI; 0 to 100 daily activities scale with 0 indicating no activities performed and 100 all 
activities performed), Stroke Impact Scale (SIS; self-reported scale of 16 activity domains from 1-most 
impaired to 5-not impaired), NIH Stroke Scale (NIHSS, clinic visits only; scores range from 0 to 42, with higher 
scores indicating a more severe neurologic deficit). CT was repeated at 30 and 365 days. The mRS 
assessment, the primary outcome, was video-recorded and sent to a core lab for blinded assessment by an 
independent panel of experts.13 All other assessments were secondary. Full details of mRS, eGOS, and 
NIHSS are given in the supplemental appendix sections 2b and 2c.   
 
Statistical Methods  
 
Sample Size: The trial planning was informed by data from the previously completed Phase II CLEAR studies, 
which recorded 30-day outcomes.6 Sample size planning assumed an average removal difference attributable 
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to alteplase of 12ml. The sample size of CLEAR III was planned to be 250 patients per group in order to 
provide at least 82% power to detect a risk difference of 13% in the proportion of good outcome from 
EVD+alteplase treatment compared to control, assuming a 22% proportion of good outcome among controls.  
The conjectured risk difference and good outcome rate under control were based on extrapolating from the 
previously completed Phase II CLEAR studies, which recorded baseline IVH clot volume and location (for ICH) 
and 30-day mRS outcomes.6 To do this, models were first fit using the data from these studies, and then used 
for simulating hypothetical trials at sample size 500 as described in section 2g of the supplemental appendix. 
 
We present data in three groups: the planned intention-to-treat (ITT) primary efficacy analyses of functional 
outcome; additional mRS efficacy analyses including other mRS analyses of various cut points, and secondary 
analyses of case fatality, clot removal, and ICU care; and safety. Adjusted analyses are indicated in Table S1. 
The primary and key secondary analyses were designated in 2008, at the start of the trial.  
 
ITT Efficacy Analysis: The primary aim was to assess clinical efficacy of EVD+alteplase by estimating the 
difference in the proportion of centrally-adjudicated mRS scores, dichotomised as ≤3 vs. >3, at 180 days. We 
estimated the average benefit comparing treatment vs. control, using the ITT principle. Specifically, we 
estimated the difference between the probability of 180-day mRS ≤3, referred to as a good outcome, 
comparing alteplase vs. saline. In accordance with the literature on covariate-adaptive randomised designs, 
the estimate of the adjusted treatment effect was based upon a weighted average of the difference in 
proportions for each of the six strata defined by the possible baseline combinations for covariates used in 
randomization: IVH volume and location. Weights were set proportional to the number in each stratum (pooled 
across arms). The 95% confidence interval, estimated by the percentile method for the average treatment 
effect, was computed by the nonparametric bootstrap method, such that the covariate-adaptive design is 
adhered to in each resampled (i.e., bootstrap replicated) data set. Multivariable logistic regression models were 
used to estimate the conditional effect of treatment on good mRS outcome for baseline variables.  
 
Secondary and Post-hoc Efficacy Analysis: Planned secondary efficacy analyses: 1) The Kaplan-Meier 
time-to-event analysis was used to estimate the survival functions and the log-rank test was used to compare 
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the survival by treatment. 2) A logistic model relating clot removed to mRS 0-3 proportion was used 
(Supplemental Table S2). These models were informed by univariate regression and well established clinical 
and epidemiologic considerations of the important prognostic factors of age, initial Glasgow Coma Scale (GCS) 
score (scores range from 3 to 15, with lower scores indicating reduced levels of consciousness), IVH size as a 
continuous variable, and the results of the planned intervention, clot removal. 3) Intensity of ICU management 
by treatment type was compared via Chi square or Fisher’s exact test, as appropriate. Results of planned 
analyses of key demographic subgroups for heterogeneity of treatment effect: IVH and ICH size, location, 
GCS, age, gender, and race are presented.  
 
Post hoc analyses were undertaken for two unexpected but clinically important findings: 1) when the number of 
subjects in mRS 5 category at 180 days was inspected for disproportion, a treatment comparison was made. 2) 
When inspection of protocol associated clot removal showed that alteplase achieved the hypothesised 
differential removal for subjects with IVH volume >20mL but not in the group with<20mL, subgroup by 
treatment group was undertaken. Interaction terms for treatment by baseline IVH stability volume at 20mL were 
considered. No correction for multiplicity was applied, as secondary analyses were considered hypothesis 
generating.   
 
Safety Analysis: The safety aim of the trial was to achieve near total clot dissolution without procedure-related 
safety events endangering subjects beyond the risks associated with intensive medical treatment.20 Analyses 
tested the null hypothesis that use of alteplase is safe for the treatment of IVH, relative to standard care of EVD 
alone under pre-specified thresholds for 30-day case fatality (40%), symptomatic rebleeding (25%), and 
bacterial brain infection (20%). We tested these three thresholds and all safety event rates as interim analyses 
after 100, 175, 250, and 350 subjects were enrolled and then for the full 500 over 180 days with Fisher’s exact 
test. The overall occurrence rate of serious adverse events (SAEs) was tested between the two treatment 
groups. 
 
Clot Removal Analysis: End of treatment (EOT) was defined as 24 hours after the last dose.18 Additionally, 
area under the curve (AUC) of the IVH time course from stability to EOT was calculated using the trapezoidal 
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rule to quantify clot removal over time. AUC values were normalised by the time elapsed from stability to EOT 
to account for variability in treatment times. Logistic and Cox regression analyses were done to evaluate the 
relationship between IVH removal, represented by the normalised AUC of IVH clot on mRS ≤ 3, and 180-day 
case fatality, respectively, after adjustment for ICH clot location, age, ICH volume at stability and randomization 
GCS.  
 
All analyses were conducted using two-sided tests with a Type I error rate of 0.05, performed using the 
statistical packages STATA 13.0 or higher (STATA Corp, College Station, TX) and R version 3.2 (R 
Foundation for Statistical Computing, Vienna, Austria). All data are presented as median [IQR: inter quartile 
range], unless otherwise specified.  
 
Role of the Funding Source: The principal investigator (DFH) conceived, organized and executed this trial.  
He had full access to all study data and had final responsibility for the decision to submit for publication. The 
sponsor NIH/NINDS provided input regarding the study design during the grant review process and the 
NIH/NINDS-appointed DSMB provided the same during active recruitment. The NIH/NINDS-appointed DSMB 
and Genentech, Inc. approved the decision to submit the paper for publication.  
 
Results 
 
Subjects: Between September, 2009 and January, 2015, 500 patients were randomised, with the last subject 
completing follow-up in January, 2016 (Fig. 1). The trial completed with 180-day follow-up data available for 
analysis from 246/251 and 245/249 subjects in the alteplase and placebo groups, respectively. Admission 
demographics and clinical severity factors are shown in Table 1 and were similar between groups. Subjects 
arrived at hospital within 1.5 [0.8, 3.5] hours of ictus and underwent a CT by 2.3 [1.4, 4.9] hours. ICH clot 
location was thalamus 59%, 32% other; and 9% primary IVH (no identifiable ICH). The baseline IVH and ICH 
sizes were 21.8 [12.7, 36.9] mL and 7.9 [2.5, 15.0] mL, respectively. Baseline mean arterial pressure and ICP 
were similar by group. Subjects received first EVD at 7.5 [5.0, 12.0] hours and bleeding was determined stable 
by 43.5 [26.9, 57.9] hours post ictus.  
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Acute Protocol Period: Randomization occurred at 52.1 [39.1, 66.5] hours, with first treatment given 3.0 [1.7, 
5.5] hours later. Five [3, 8] alteplase and 12 [9, 12] saline doses were given. EOT occurred at 2.5 [1.8, 3.7] and 
4.7 [4.0, 5.1] days post randomization for alteplase and saline respectively. In the alteplase group, the 3rd and 
4th ventricles opened more rapidly (p<0.0001). Twenty percent of all subjects achieved 80% removal of IVH, 
10% saline and 30% alteplase. Overall, 27% of subjects received two EVDs (dual catheters), one in each 
lateral ventricle. During treatment, most subjects (78%) experienced at least one ICP reading ≥20mmHg. 
Cerebral perfusion pressure (CPP) <70 mmHg occurred in 62% of subjects despite continuous EVD drainage; 
the proportion of CPP compromise was 2% less in the alteplase arm (see Table 1). Permanent ventriculo-
peritoneal shunts were placed in 18% of subjects. 
 
Primary Efficacy Outcomes: Retention to day 180 was 98%. The primary ITT analysis comparing arms by 
mRS ≤3 outcome was 48% for alteplase and 45% for saline (RR (95% CI)=1.06 (0.88, 128), p = 0.554) (Fig. 2 
and Table 2). The difference in good outcome (alteplase – saline) adjusted for IVH size and thalamic ICH was 
3.5% (RR (95% CI)=1.08 (0.90, 1.29), p=0.420), not significantly different from zero. A single subject received 
alteplase after completion of 12 doses of saline (crossover). A subsequent sensitivity analysis was performed 
with this subject moved to the active treatment arm. The primary results did not change. 
 
Secondary Outcomes and Safety: The mRS 6 (death) category showed a 50% decrease in the odds of being 
dead (mRS 6) for alteplase versus saline (Adjusted OR (95% CI) = 0.49 (0.37, 0.81), p = 0.001) (Table 3). No 
effect of hospital site was demonstrated for the primary mRS 0-3 outcome. (See Supplemental Table S1.) 
Estimated Kaplan-Meier survival probabilities were greater throughout 180 days of follow-up for the alteplase 
group (cumulative case fatality: 18% vs. 29%; p=0.006) (Fig. 3). Safety parameters favoured alteplase: 
bacterial ventriculitis (7% vs. 12%; RR (95% CI)=0.55 (0.31, 0.97), p=0.048) and SAEs (49% vs. 63%; RR 
(95% CI)=0.77 (0.66, 0.91), p=0.002). The frequency of symptomatic bleeding was similar between groups (2% 
in both arms; RR (95% CI)=1.21 (0.37, 3.91), p = 0.771). Table S1 in the supplemental appendix shows the 
primary, secondary and safety outcomes. Table 4 shows the safety profile by group and by the Medical 
Dictionary for Regulatory Activities (MedDRA) body system classifications. 
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A post-hoc analysis of the mRS 5 (i.e., bedbound) category shows a greater proportion in the alteplase group 
(17% vs. 9%; RR (95% CI)=1.99 (1.22, 3.26), p =0.005). Other post-hoc analyses demonstrated no difference 
in the proportion of subjects in a vegetative state, measured by the eGOS scale (3% in both groups; RR (95% 
CI)=1.33 (0.47, 3.78), p =0.787) nor for subjects surviving in long-term care facilities (alteplase 14% vs. saline 
12%; RR (95% CI)=1.18 (0.74, 1.88), p =0.479) (see Fig. 2 and Table S2). Neither Barthel index nor EuroQol 
Visual Analog Scale (EQ-VAS; self-reported, quality of life scale with scores ranging from 0-worst to 100-best 
imaginable health state) was different between groups (see Table S1). 
 
Clot Removal: Removal of clot varied widely, dependent on number and location of EVDs and number of 
alteplase doses. Thirty percent (30%) of the alteplase group and 10% of the saline group achieved the 80% 
removal endpoint. The planned secondary analysis relating mRS to the amount and timing of clot removal in all 
subjects demonstrated a significant relation between clot removal (per clot remaining (mL), as measured by 
normalised AUC) and both mRS ≤3 (AOR (95% CI)=0.96 (0.94, 0.97); p <0.0001) and case fatality (AHR (95% 
CI) of death per mL of time-weighted clot volume remaining = 1.03 (1.02, 1.04); p <0.0001), adjusted for age, 
thalamic ICH location, stability ICH volume, and randomised GCS (see Supplemental Table S3). The results of 
the subgroup analyses pre-specified in the protocol are shown in Supplemental Figure S1. No p values for 
interaction were significant.  
 
Discussion 
 
In the CLEAR III trial, irrigation of the ventricles with alteplase via a routine EVD did not improve functional 
outcomes in patients with IVH. Analyses of our secondary outcome measures, 180 day case fatality was 
significantly lower in the alteplase group, but the majority of these survivors ended up with severe disability 
(i.e., mRS4,5 or eGOS lower and upper significant disability). Clot removal analyses showed a correlation 
between amount of removal and improved mRS ≤3. Alteplase appears safe when compared to saline. These 
findings suggest possible value to the concept of removing greater amounts of IVH volume. On the face of the 
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current evidence, however, alteplase at the dose of 1 mg every 8 hours cannot be recommended as an 
intervention to improve functional outcome in patients with IVH.  
 
There are limitations to this trial. This was the first Phase III IVH thrombolysis trial and evidence-based 
standards for subject selection and treatment endpoint did not exist. Current guidelines do not mandate the 
use, number, or location of EVD catheters, which are important factors influencing the amount of IVH removed. 
Routine practice produced good adherence to EVD safety, and opening of the midline ventricles occurred; but, 
poor adherence to removal of >80% IVH. This lack of adherence may have limited the stringency of the test of 
our hypothesis. Not all severity factors are known, so imbalances in severity could have existed. For example, 
nonspecific factors (e.g., type and extent of ICU care) could have been different between the treatment arms 
and influenced outcomes. For ICU care this does not seem likely, as subject severity, “withdrawal of care,” and 
ICU care were similar between groups. CLEAR III was a small sample of current clinical practice taken from 
the most aggressive end of the treatment spectrum: those subjects whose physicians utilised EVDs. The 
control intervention represents an aggressive level of care not always offered to every subject with IVH. The 
baseline mortality and good functional outcomes observed in the CLEAR III controls was greater than in our 
prior study6 or in the expected levels from the general population (where low frequencies of EVD use are 
coupled with very high reliance on medical care as the sole supportive intervention for IVH).2,3,6,7,9 Only 
convenience sample data exists for outcomes of medically managed subjects thus our knowledge about risk 
and benefit for the intervention in the general population is limited. Another possible limitation is that the 
CLEAR III sample might not represent a true general IVH population, rather a milder or more severe 
population. Evaluations of the general population of IVH, concurrently performed, have demographics and 
severity factors matching CLEAR III. They show full population estimates of mortality (40%-60%) and low good 
functional outcome (10%-30%) suggesting less intense therapies may not produce as many benefits.2,5 Finally, 
the main outcome measure: mRS 0-3 vs. 4-6 proportion is only one measure of disability. Further research will 
be needed to clarify the divergent picture within the more severe disability segments of mRS and eGOS.21 If 
survival comes at the cost of living with unacceptable impairment, this or any treatment could be seen as 
limited in value.   
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Potential to improve practice is evident with the findings that CPP/ICP are not always controlled by a single 
EVD routinely placed into the anatomically largest pool of cerebrospinal fluid or least bloody site. This is a 
starting point for investigating multiple catheters where clot is large, bilateral, trapping the ventricle, or creating 
a local mass effect. Placing a second catheter near or into the largest portion of the clot leads to greater and 
more rapid removal22 and possibly greater clinical benefit. The precise clinical definitions for the at-risk 
population will need to be tested in a surgically-standardised trial setting.23 The signal of benefit from greater 
clot removal and the low percentage of subjects achieving 80% removal raise the possibility that benefit of 
alteplase may be possible if greater clot removal could be achieved and, if it is achieved, more rapidly. As 
CLEAR III did not demonstrate improved rates of good functional recovery with alteplase rather than saline, 
future investigation will need improved surgical placement of catheters to achieve effective clot reduction more 
frequently and more rapidly. A possible solution is an adaptively-designed, efficacy-to-effectiveness trial24 that 
demonstrates a better clot removal protocol can be integrated into routine stroke care and tests for influence 
on function, disability and case fatality.   
 
Panel: Research in Context 
 
Evidence before this study: A literature search was done from January 1, 1950 until November 1, 2015 on 
PubMed with the terms: IVH, IVH AND ICH, IVH AND TPA, IVH AND thrombolytic, IVH AND cross 
sectional, and IVH AND treatment. Search filters for "adult" and "human subjects" publications were 
applied.  Meta-analysis of case series, one small multisite trial, and single-site convenience samples suggest 
mortality and perhaps functional impairment can be mitigated via enhanced clearance of the IVH through 
thrombolysis. Prior to and after the Clot Lysis: Evaluating Accelerated Resolution of IVH Phase III (CLEAR III) 
trial, when caring for patients with a small ICH and large IVH, clinicians have no class 1 evidence regarding the 
safety and effectiveness of IVH thrombolysis.  
 
Added value of this study: CLEAR III is a randomised, double-blinded study designed to provide a test of the 
combination of extraventricular drainage (EVD) and low dose thrombolytic as a method of removing IVH and 
improving functional outcomes. This multisite study is the first to prospectively collect several objective 
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functional performance (modified Rankin Scale [mRS] and extended Glasgow Outcome Scale [eGOS]) as well 
as patient-based (Euro –QoL [EQ], Stroke Impact Scale [SIS]) measures of satisfaction. Medical care in the 
intensive care unit (ICU) was standardised and assessed rigorously. Data were prospectively defined and 
collected in a uniform manner and monitored thoroughly providing evidence of type, intensity and duration of 
ICU care required. Precise measurement of IVH size occurred in this trial possibly improving estimates of 
severity and treatment performance. The results of CLEAR III provide a robust estimate of the proportion of 
mRS 0-3 (approximately 45% to 48%) that occurs, if subjects are supported until the EVD is no longer needed. 
This led to an adjusted (IVH size and thalamic location) estimate of treatment effect of 3.5% (95% CI -4%, 
12%). This effect size was not different between alteplase and saline treatment plans, though case fatality did 
differ. The absolute proportion of mRS 0-3 found in all CLEAR III subjects compares favourably to the 
untreated subjects in the literature. The study provides detailed evidence that a protocoled approach to remove 
IVH with alteplase is safe and that the 3rd and 4th ventricles open sooner if alteplase is utilized.  A legitimate 
concern could be raised about greater infection rates due to frequent injections of alteplase or saline in the 
EVD, however a comparison of infection rate in CLEAR is in the same range as that reported in a meta-
analysis of infections from published EVD series where injections were not performed. The data presented 
characterise substantial variations in current EVD-related neurosurgical practice. They demonstrate usefulness 
of the measures of initial severity (Glasgow Coma Scale [GCS], location, and ICH/IVH size) and the elements 
of treatment needed for precise characterization of prognosis in the aggressively treated IVH patient. The sub-
group analysis suggests increased focus on larger IVH and earlier treatment times is appropriate. 
 
Implications of all the available evidence: The trial was neutral on primary outcome of functional improvement. 
Therefore we do not think practice should change. Other post hoc results are consistent with the hypothesis 
that removal saves lives and possibly improves function. The issue of survival with disability is now well 
defined by our primary results and other measures of disability. The secondary results leave open a possible 
role of IVH volume reduction as a biomarker for treatment, with better outcomes more likely achieved with 
enhanced IVH clearance, particularly in subjects with larger initial IVH volume. The results are consistent with 
prior convenience reports and meta-analyses that good functional outcome can occur in up to 50% of treated 
subjects. The data provide a sound basis to critically redefine short-term neurosurgical and ICU management 
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around the task of volume removal. A trial testing these more objective goals is needed, if we are to be 
assured that aggressive removal of IVH is safe and can predictably produce increased independent function 
and decreased case fatality. Current information suggests as many as 25% of ICHs have large IVH.  How 
many of these patients receive care and would be eligible for treatment is not known.  An estimate of the full 
benefit of intervention will require a combined epidemiological and RCT intervention approach that randomises 
available subjects and collects information about usual care controls. A novel trial would provide a 
standardised surgical task, treat subjects more rapidly and require greater care team adherence to the removal 
of large amounts of the IVH, not just removal of enough blood clot to open the 3rd and 4th ventricles. Sharing 
the full results of CLEAR III is likely to stimulate further investigations of a worldwide problem that is serious, 
growing, and could be treatable.  
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Table Notes and Figure Legends  
 
Table Notes 
 
Table 1. Demographic and Baseline Subject Characteristics by Group.  
 
Table 2. Treatment Variables by Group. Additional Outcome Variable Data are Included as Table S4 in the 
Supplementary Materials. 
 
Table 3. mRS Score Frequencies for the 30, 180, and 365 Day Time Points. The 180-Day Data Represent the 
Primary, Unadjusted Outcome. Corresponding eGOS Data for the Same Time Points Can Be Seen in 
Supplemental Table S3. In the alteplase group, one subject who was initially thought to be lost to follow-up at 
day 30 was located and evaluated at day 180. 
 
Table 4. SAEs by treatment group. This listing shows fewer neurologic, respiratory, and sudden deaths (found 
in the MedDRA general disorders classification) in the alteplase group. This is consistent with the hypothesis 
that early removal of blood corrects a severe life threatening cerebral anatomic defect and possibly limits the 
structural brain injury as well as limits the effects of immobility on cardiorespiratory risks inherent with structural 
brain injury.   
 
Figures Legends 
 
Figure 1. CONSORT diagram. The CONSORT diagram summarizes the number of subjects that progressed 
through the enrollment, allocation, and follow-up periods of the trial. In the alteplase group, one subject who 
was initially thought to be lost to follow-up at day 30 was located and evaluated at day 180. 
 
Figure 2. Outcome dichotomies of mRS (left panel; scores range from 0 [no disability] to 6 [death]) and eGOS 
(right panel; scores range from 8-upper good recovery to 1-death) scores at 30 and 180 days by treatment. 
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The left panel blue lines indicate the differences in proportion of 180-day mRS ≤ 3 (45% in saline vs. 48% in 
alteplase; p=0.477) and deceased subjects (30% in saline vs. 19% in alteplase; p=0.09).  
 
Figure 3. Kaplan-Meier survival estimates with truncation at 193 days for late and missed 180-day visits 
(n=36), which corresponds to the longest “in-window” 180-day visit. Estimated survival probabilities were 
higher throughout 180 days of follow-up with alteplase compared to the saline group (p=0.006). 
 
Table 1 
 
 
Alteplase 
(N=249) 
Saline 
(N=251) 
Demographic variables   
Age in Years: Median [IQR] 59 [51, 66] 59 [51, 67] 
Gender: Female: no. (%) 105 (42) 117 (47) 
Race   
White: no. (%) 144 (58) 161 (64) 
African American: no. (%) 92 (37)  78 (31)  
American Indian or Alaskan Native: no. (%) 0 (0)  1 (<1)  
Other: no. (%) 13 (5) 11 (4) 
      Ethnicity: Hispanic/Latino: no. (%) 28 (11) 32 (13) 
Baseline variables   
Tobacco Use: no. (%) 73 (29) 59 (24) 
Cocaine Use: no. (%) 12 (5) 18 (7) 
Anticoagulated at Registration: no. (%) 20 (8) 29 (12) 
Antihypertensive Med Compliant (self-report): no. 
(%) 168 (67)  202 (80)  
Hyperlipidemia Med Compliant (self-report): no. (%) 240 (96)  245 (98)  
On Antiplatelet at Registration: no. (%) 56 (22) 72 (29) 
     Randomization MAP: Median [IQR] 96 [86, 106] 94 [86, 104] 
     Randomization GCS† Total: Median [IQR] 10 [7, 13] 9 [7, 12] 
     Randomization NIHSS: Median [IQR] (N=231) 19 [11, 32] 
(N=232) 
20 [11, 35] 
Stability CT (last CT prior to enrollment) 
IVH Volume (mL): Median [IQR] 
ICH Volume (mL): Median [IQR] 
21.2 [12.6, 36.1] 
8.2 [2.8, 15.2] 
22.4 [12.7, 39.1] 
7.2 [2.3, 14.7] 
Index Clot Location 
     Thalamus: no. (%) 149 (60) 144 (57) 
     Primary IVH: no. (%) 18 (7) 27 (11) 
Ictus to Hospital Arrival (hrs.): Median [IQR] 1.5 [0.8, 3.4] 1.5 [0.8, 3.6] 
Ictus to 1st CT (hrs.): Median [IQR] 2.3 [1.3, 4.6] 2.3 [1.4, 5.2] 
Ictus to 1st EVD (hrs.): Median [IQR] 7.0 [4.5, 11.8] 7.9 [5.0, 12.0] 
Ictus to Stability CT (hrs.): Median [IQR] 43.0 [25.4, 58.9] 44.0 [28.2, 57.0] 
Ictus to Randomization (hrs): Median [IQR] 51.8 [36.4, 65.8] 52.2 [41.2, 66.8]   
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Table 2  
 
 
Alteplase 
(N=249) 
Saline 
(N=251) p-value 
Treatment Variables    
Randomization to 1st Dose (hrs.): Median [IQR] 3.0 [1.7, 5.3] 3.1 [1.7, 5.7] 0.62 
Total number of Doses:  Median [IQR] 5 [3, 8] 12 [9, 12] <0.001 
Duration of Dosing (days): Median [IQR] 1 [1, 2] 4 [3, 4] <0.001 
Randomization to EOT (days): Median [IQR] 2.5 [1.8, 3.7] 4.7 [4.0, 5.1] <0.001 
EOT IVH Volume (mL): Median [IQR] 5.9 [1.9, 13.0] 11.5 [5.8, 23.1] <0.001 
Time to Open Ventricles (days): Median [IQR] 2 [2,3] 5 [3,7] <0.001 
ICP ≥20 mmHg: Mean proportion of events (mean 
of patient-specific proportions) 9.8 10.2 0.45 
CPP <70 mmHg was lower with alteplase: no. (%) 644(7) 867(9) <0.001 
One or more ICP Therapy(ies): no. (%) 67 (27) 77 (31) 0.35 
Dual EVD Placed: no. (%) 66 (27) 71 (28) 0.66 
Day 0-180 Bacterial Ventriculitis: no. (%) 17 (7) 31 (12) 0.05 
Symptomatic Bleeding ≤72 hr. post Last Dose: no. 
(%) 6 (2) 5 (2) 0.77 
SAEs: no. (%) 121 (49) 158 (63) 0.002 
Days in ICU: Median [IQR] 14 [11, 21] 15 [12, 22] 0.10 
Withdrawal of Care: no. (%)  27 (11) 30 (12) 0.70 
Ventilator Support: no. (%) 184 (74) 192 (76) 0.50 
Pressor/Inotrope use: no. (%) 60 (24) 63 (25) 0.79 
Ventriculoperitoneal Shunt: no. (%) 46 (18) 44 (18) 0.78 
†Scores on the Glasgow Coma Scale (GCS) range from 15 (fully conscious) to 3 (deep coma) 
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Table 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Visit and Treatment 
 30 days 180 days 
mRS 
Saline 
(n=249) 
Alteplase 
(n=245) 
Saline 
(n=245) 
Alteplase 
(n=246) 
0 4 1.61% 2 0.82% 11 4.49% 6 2.44% 
1 2 0.80% 4 1.63% 13 5.31% 19 7.72% 
2 7 2.81% 17 6.94% 31 12.65% 34 13.82% 
3 28 11.24% 27 11.02% 55 22.45% 58 23.58% 
4 46 18.47% 51 20.82% 41 16.73% 41 16.67% 
5 126 50.60% 122 49.80% 21 8.57% 42 17.07% 
6 36 14.46% 22 8.98% 73 29.80% 46 18.70% 
         
Total 249 100.00% 245 100.00% 245 100.00% 246 100.00% 
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Table 4 
 
Body System Alteplase Saline  
Blood and lymphatic disorders 0 1  
Cardiac disorders 7 14  
Gastrointestinal disorders 4 1  
General disorders and admin site conditions 22 34  
Hepatobiliary disorders 1 0  
Infections, non-neurologic 12 6  
Injury, poisoning and procedural complication 5 3  
Investigations (laboratory) 0 1  
Metabolism and nutrition disorders 0 1  
Musculoskeletal & connective tissue disorders 0 2  
Nervous system disorders 40 53  
Psychiatric disorders 1 2  
Renal and urinary disorders 2 2  
Respiratory, thoracic & mediastinal disorders 22 33  
Surgical and medical procedures 1 1  
Vascular disorders 4 4  
Total 121 158  
Percentage 48.6% 62.9% p=0.0016 
    
 
 
 
 
 
 
 
 
 
 
